GFPC 03-2013 / FLARE

PROTOCOL FLARE /GFPC 03-2013

A multicenter randomized phase III study comparing second-line treatment with chemotherapy associated or not to erlotinib in NSCLC patients with secondary resistance to TKI-EGFR